New Product - Strensiq
Strensiq (asfotase alfa (rch)) is a human recombinant tissue nonspecific alkaline phosphatase (TNSALP)-Fc-deca-aspartate fusion protein with enzymatic activity. Asfotase alfa promotes mineralisation of the skeleton in hypophosphatasia (HPP). Strensiq is indicated as enzyme replacement therapy in paediatric onset HPP. Asfotase alfa is contraindicated with known hypersensitivity to Chinese hamster ovary cell proteins. Strensiq is available in two strengths, 40 mg/mL (18 mg/0.45 mL, 28 mg/0.7 mL and 40 mg/1 mL single use vials in packs of 12’s) and 100 mg/mL (80 mg/0.8 mL single use vials in packs of 12’s).
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629